Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

7.8%

8 terminated/withdrawn out of 103 trials

Success Rate

91.8%

+5.3% vs industry average

Late-Stage Pipeline

31%

32 trials in Phase 3/4

Results Transparency

82%

73 of 89 completed trials have results

Key Signals

2 recruiting73 with results6 terminated

Enrollment Performance

Analytics

Phase 2

37(41.6%)

Phase 3

21(23.6%)

Phase 4

11(12.4%)

N/A

10(11.2%)

Phase 1

10(11.2%)

89Total

Phase 2(37)

Phase 3(21)

Phase 4(11)

N/A(10)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (103)

Showing 20 of 103 trials

NCT06205589Phase 2Not Yet Recruiting

Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

Role: lead

NCT04860323Not ApplicableCompleted

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Role: collaborator

NCT04843761Phase 3Completed

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Role: collaborator

NCT06729593Phase 3Completed

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Role: collaborator

NCT06729606Phase 3Completed

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Role: collaborator

NCT00031408Active Not Recruiting

Consent for Use of Stored Patient Specimens for Future Testing

Role: lead

NCT02563327Phase 3Completed

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Role: collaborator

NCT02859558Phase 2Completed

Early ART to Limit Infection and Establishment of Reservoir

Role: lead

NCT06031272Phase 1Active Not Recruiting

Pausing Antiretroviral Treatment Under Structured Evaluation

Role: lead

NCT06856174Phase 4Not Yet Recruiting

Menopausal HT for Women Living With HIV (HoT)

Role: lead

NCT04636437Phase 4Completed

Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

Role: lead

NCT04801758Not ApplicableCompleted

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

Role: collaborator

NCT05780437Phase 3Completed

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT06205602Phase 2Recruiting

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

Role: lead

NCT02840474Phase 1Completed

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

Role: collaborator

NCT03001128Completed

Biomarkers to Predict Time to Plasma HIV RNA Rebound

Role: lead

NCT05156658Phase 4Withdrawn

Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

Role: lead

NCT05985642Recruiting

Observational PIC Destination Cohort

Role: lead

NCT02410772Phase 3Completed

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens